Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.63 |
| ▸ | CES1 | P23141 | 4/20 | 0.63 |
| ▸ | BCHE | P06276 | 1/20 | 0.63 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | MMP3 | P08254 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MPO | P05164 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29382881 | 0.83 | GAA (0.67) | CES2CES1GAAMMP3HDAC8 | |
| SCHEMBL298653 | 0.83 | GAA (0.67) | CES2CES1GAAMMP3HDAC8 | |
| SCHEMBL28471319 | 0.82 | CES2 (0.61) | CES2CES1BCHEKAT6AGAA | |
| SCHEMBL28709174 | 0.82 | HDAC8 (0.48) | CES2CES1BCHEGAAMMP3 | |
| SCHEMBL1805144 | 0.82 | GAA (0.71) | CES2CES1BCHEKAT6AGAA | |
| SCHEMBL29599784 | 0.82 | HDAC8 (0.48) | CES2CES1BCHEGAAMMP3 | |
| SCHEMBL2646708 | 0.82 | CES2 (0.61) | CES2CES1BCHEKAT6AGAA | |
| SCHEMBL8777114 | 0.81 | CES2 (0.61) | CES2CES1BCHEGAAMMP3 | |
| Hydrochloric Acid SCHEMBL28973500 | 0.81 | GAA (0.64) | CES2CES1GAAMMP3HDAC8 | |
| SCHEMBL10772687 | 0.79 | CES2 (0.57) | CES2CES1BCHEKAT6AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169816-B2 | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
| US-20060052608-A1 | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors | WARNER-LAMBERT COMPANY LLC | 2006-03-09 | — | — | US | disclosed |
| US-20050049429-A1 | 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors | BARRETT STEPHEN DOUGLAS (US) | 2005-03-03 | — | — | US | disclosed |
| US-6821963-B2 | PHENYLAMINO BENZHYDROXAMIC ACID DERIVATIVES INHIBIT CERTAIN DUAL SPECIFICITY KINASE ENZYMES INVOLVED IN PROLIFERATIVE DISEASES SUCH AS CANCER, PSORIASIS AND RESTENOSIS; INHIBIT THE PHOSPHORYLATION OF MAP KINASE BY MEK | WARNER-LAMBERT COMPANY | 2004-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052608-A1 | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors | BRAF, MAPK1, MAPK4 | CES2 3554/4885CES1 1382/4885BCHE 3719/4885 |
| US-20050049429-A1 | 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors | BRAF, MAPK1, MAPK4 | CES2 3554/4885CES1 1382/4885BCHE 3719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.